Assessment of fractionated exhaled nitric oxide as a biomarker for the treatment of eosinophilic esophagitis

作者：Leung John^*; Nguyen Traxler Ann; Lee Erika M; Yip Jason S; Weinstock Joel V; Chan Walter W; Ngo Peter; Weinstein Barbara J; Bonis Peter A

来源：Allergy and Asthma Proceedings, 2012, 33(6): 519-524.

DOI：10.2500/aap.2012.33.3606

Diagnosis of eosinophilic esophagitis (EoE) and determination of response to therapy is based on histological assessment of the esophagus, which requires upper endoscopy. In children, in whom a dietary approach is commonly used, multiple endoscopies are needed, because foods are eliminated and then gradually reintroduced. Ideally, noninvasive methods could supplement or replace upper endoscopy to facilitate management. Fractionated exhaled nitric oxide (FeNO) has been proposed as a useful measure for monitoring disease activity in studies of patients with eosinophil-predominant asthma and in other atopic disorders. Thus, we should evaluate whether FeNO levels could be a useful biomarker to assess response to therapy in EoE patients. This study was designed to determine whether there is a change in FeNO levels during treatment with topical corticosteroids and whether changes correlated with clinical response. This was a prospective, multicenter study that enrolled nonasthmatic patients with established EoE. FeNO level and symptom scores were measured at baseline, biweekly during 6-week swallowed fluticasone treatment, and 4 weeks posttreatment. Twelve patients completed the trial. We found a statistically significant difference between median pre- and posttreatment FeNO levels; a change of FeNO level after 2 weeks of treatment or FeNO level at the end of treatment confidently predicted a clinical or histological response. Although our findings suggest nitric oxide possibly has a physiological role in EoE, our observations do not support a role of FeNo determination for management of EoE. (Allergy Asthma Proc 33:519-524, 2012; doi: 10.2500/aap.2012.33.3606)

• 出版日期2012-12